Maggie Tibbitt


TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

October 21st 2021

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.

Lisaftoclax Elicits Responses With a Tolerable Safety Profile in Relapsed/Refractory CLL

October 20th 2021

Sikander Ailawadhi, MD, discusses the unique pharmacodynamic profile of lisaftoclax, the similar responses seen across cohorts, and the favorable tolerability of the drug.

Miami Cancer Institute’s HIV/Cancer Clinic Utilizes Multidisciplinary Care to Improve Outcomes

October 15th 2021

Marco Ruiz, MD, discusses the new HIV/Cancer Clinic and its goals, challenges faced with patients who have cancer and HIV infection, and clinical trial opportunities that strive to move the needle forward.

Choueiri Shares Highlights From the 2021 Kidney Cancer Research Summit

October 14th 2021

Toni Choueiri, MD, discusses key highlights from the 2021 Kidney Cancer Research Summit and exciting research efforts underway in renal cell carcinoma.

Entospletinib Plus Obinutuzumab Shows Early Efficacy, Tolerability in High-Risk Relapsed/Refractory CLL

October 13th 2021

Alexey Danilov, MD, PhD, discussed the data on entospletinib/obinutuzumab in patients with R/R CLL and suggests further research directions with this drug combination.

Harbeck Highlights Biomarkers for pCR, Survival After De-escalated Neoadjuvant T-DM1 in HER2+ Breast Cancer

October 7th 2021

Nadia Harbeck, MD, PhD, discusses the predictive impact of biomarkers on pathologic complete response and survival following de-escalated neoadjuvant T-DM1 with or without endocrine therapy in patients with hormone receptor–positive, HER2-positive breast cancer.

Frontline Ibrutinib Shows Sustained Survival Advantage Over Chlorambucil in CLL at 7 Years

October 6th 2021

Tadeusz Robak, MD, discussed the 7-year safety and efficacy data from the RESONATE-2 trial examining frontline ibrutinib in CLL.

Monk Reviews Transformative KEYNOTE-826 Data in Cervical Cancer and Next Steps for Research

October 5th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

Cemiplimab/Chemo Represents New Frontline Option for Advanced NSCLC Without Actionable Mutations

October 4th 2021

Miranda Gogishvili, MD, discusses the rationale for examining cemiplimab plus platinum-doublet chemotherapy as a frontline treatment in patients with advanced NSCLC and key findings from the phase 3 EMPOWER-Lung 3 trial.

Catequentinib Proves Efficacious, Well Tolerated in Synovial Sarcoma

October 1st 2021

Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.

Durvalumab Plus Olaparib or Cediranib Leads to Disease Stabilization in Leiomyosarcoma

September 23rd 2021

Albiruni Ryan Abdul Razak, discusses the rationale for examining durvalumab with either olaparib or cediranib in patients with LMS, key data reported with this approach, and next steps for the phase 2 DAPPER study.

Acalabrutinib Demonstrates Improved Tolerability, Similar Efficacy to Ibrutinib in CLL

September 15th 2021

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

Neoadjuvant Talazoparib Shows Activity in BRCA1/2+ Early HER2-Negative Breast Cancer

August 30th 2021

Jennifer K. Litton, MD, discusses the rationale for examining neoadjuvant talazoparib in patients with BRCA1/2-positive, early HER2-negative breast cancer, safety and efficacy results from NEOTALA, and next steps for research.

Niraparib Maintains Safety, Efficacy in BRCA+ Ovarian Cancer, Irrespective of Setting

August 12th 2021

Maintenance niraparib has been shown to result in a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer following response to platinum-based chemotherapy.